NASDAQ:COLL Collegium Pharmaceutical Q3 2024 Earnings Report $22.64 +0.19 (+0.85%) Closing price 04:00 PM EasternExtended Trading$22.99 +0.35 (+1.56%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Collegium Pharmaceutical EPS ResultsActual EPS$1.61Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACollegium Pharmaceutical Revenue ResultsActual Revenue$159.30 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACollegium Pharmaceutical Announcement DetailsQuarterQ3 2024Date1/8/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCollegium Pharmaceutical's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Collegium Pharmaceutical Earnings HeadlinesCollegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer SaysSeptember 23 at 9:14 PM | finance.yahoo.comOppenheimer initiates coverage of Collegium Pharmaceutical with outperformSeptember 23 at 11:13 AM | msn.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 24 at 1:00 AM | Paradigm Press (Ad)Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 23 at 4:06 AM | americanbankingnews.comH.C. Wainwright Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)September 22 at 6:51 PM | theglobeandmail.comAnalyzing Ardelyx (NASDAQ:ARDX) & Collegium Pharmaceutical (NASDAQ:COLL)September 20, 2026 | americanbankingnews.comSee More Collegium Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Collegium Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Collegium Pharmaceutical and other key companies, straight to your email. Email Address About Collegium PharmaceuticalCollegium Pharmaceutical (NASDAQ:COLL) is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs. Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain. These products are marketed primarily in the United States. The company expanded beyond pain management through its acquisition of Ironshore Therapeutics, adding a portfolio of ADHD medicines that includes Jornay PM, Mydayis, Quillivant XR, Quillichew ER, Dyanavel XR and Evekeo ODT. Collegium was founded in 2002 and is headquartered in Stoughton, Massachusetts. It sells its products through commercial and specialty-pharmacy channels and works with healthcare professionals and patients throughout the U.S.View Collegium Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
